

Difference Metabolites Induced By Deoxynivalenol in Serum and Urine of Weaned Rabbits Detected Using LC-MS Based Metabolomics

Fuchang Li

Shandong Agricultural University

Libo Huang

Shandong Agricultural University

Quancheng Liu

Shandong Agricultural University

Pengwei Wang

Shandong Agricultural University

Hongju Chen

Shandong Agricultural University

Chunyang Wang (✉ wcy@sdau.edu.cn)

Shandong Agricultural University <https://orcid.org/0000-0002-6707-2274>

Research

Keywords: Deoxynivalenol, weaned rabbits, metabolomics, pathogenic mechanism, biomarker

Posted Date: November 18th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-107751/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Difference metabolites induced by Deoxynivalenol in**
2 **serum and urine of weaned rabbits detected using**
3 **LC-MS based metabolomics**

4
5 Fuchang Li^{1,#}, Libo Huang^{1,#}, Quancheng Liu¹, Pengwei Wang¹, Hongju Chen¹,
6 Chunyang Wang^{1,*}

7
8
9 ¹ Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention,
10 College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Taian, Shandong,
11 271018, China. [#] Co-first author: Fuchang Li and Libo Huang contributed equally to this work.

12 * Correspondence: +86-13-50548-0263; wcy@sdau.edu.cn

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Abstract**

40 **Background:** The main toxin effects of Deoxynivalenol (DON), which known as one
41 of the mycotoxins with the highest pollution rate, is the result of long-term accumulation,
42 and there are no obvious clinical signs at the early stage. Specific metabolites in blood
43 and urine can be used as biomarkers and become an important diagnostic indicator for
44 DON poisoning monitoring. At present, studies on the metabolic pathways and
45 characteristics of DON mainly focus on humans, pigs and poultry, but few study on
46 rabbits. This study aims to reveal the difference in DON-induced metabolites in the
47 serum and urine of weaned rabbits, so as to help find potential biomarkers and
48 understand the mechanism of DON in rabbits.

49 **Methods:** A total of 32 weaned rex rabbits were divided evenly into two groups, namely
50 the control group and DON group. Both groups of rabbits were fed with the basic diet.
51 Rabbits in DON group were intraperitoneally injected with DON at 1.5 mg/kg b.w. every
52 two days before feeding, while rabbits in control group were injected with saline at 1.5
53 mg/kg b.w. in the same way. After the 25-day trial, the serum and urine samples at
54 different experimental period were collected for LC/MS analysis.

55 **Results:** The results based on the LC-MS/MS method showed that DON can be
56 metabolized rapidly in blood, and urine is the main metabolism pathway for DON. The
57 data based on metabolomics illustrated that underlying biomarkers in serum were
58 mainly involved in Glycerophospholipid metabolism, Tryptophan metabolism and
59 Pentose and glucuronate interconversions, while those in urine samples involved in
60 Caffeine metabolism, Glycine, serine and threonine metabolism, and Terpenoid backbone

61 biosynthesis. Correlation analysis suggested that DON can induce the changes in certain

62 disease-related metabolites in serum and urine.

63 **Conclusions:** The pathogenic mechanism of DON includes multiple levels, indicating

64 that DON poisoning is caused by multiple factors acting on multiple links.

65 **Keywords:** *Deoxynivalenol, weaned rabbits, metabolomics, pathogenic mechanism, biomarker.*

66 **Background**

67 Contamination of agricultural products caused by natural mycotoxins has been a
68 long-standing challenge for agriculture and food industries [1]. Deoxynivalenol (DON),
69 widely detected in cereal grains and animal feed worldwide, is considered to be a
70 underlying health hazard for humans and animals [2,3]. Consuming contaminated DON
71 can induce physiological abnormalities, including digestive disorders, intestinal-barrier
72 damage, immune disruption and reproductive toxicity, etc [4,5].

73 Toxicokinetics studies have shown that DON ingested orally can be rapidly absorbed
74 into the blood circulation through the body's small intestinal barrier, then distribute to
75 peripheral organs, as well as affect the function of histocyte [6]. DON is degraded into a
76 variety of metabolic products in the digestive tract by microorganisms or in the intestinal
77 mucosa, liver, kidney and other organs of the body [7]. The metabolic characteristics of
78 DON in humans and animals, including the toxicological kinetics of DON absorption,
79 distribution, metabolism and excretion, are the basis for the toxicity assessment, toxicity
80 mechanism and intervention techniques of DON [8]. Therefore, studies concerning the
81 metabolic characteristics of DON have attracted wide attention. Compared with T2 toxin
82 of the congeneric trichothecenes, the identified metabolites of DON are relatively less,
83 mainly including: DON-GlcA, DON-sulfonate and DON-sulfate etc [9,10]. Among them,
84 de-epoxidation deoxynivalenol (DOM), mainly acted as a type of metabolite produced by
85 DON under the catalysis of intestinal microorganisms, which is most common metabolite
86 of DON in different species (such as humans, rodents, pigs, chickens and ruminants)
87 [11,12]. Therefore, it is generally believed that DOM-1 is the most typical biomarker of

88 DON and has been applied in relevant studies, such as the evaluation of metabolism and
89 biological detoxification of DON and so on [13,14]. However, detection cost of DOM-1 is
90 relatively high, and further research is needed to reveal whether there are other
91 biomarker in DON.

92 Clinically, most DON poisoning is the result of long-term accumulation, and there are
93 no obvious clinical signs at the early stage [15]. Therefore, it is particularly urgent to find
94 new specific and highly sensitive diagnostic indicators and methods. Blood and urine are
95 the most common physiological samples in clinical tests. The distribution and
96 elimination rate of DON and its metabolites in blood and urine is important parameters
97 for its pathogenicity[8]. Specific metabolites in blood and urine can be used as biomarkers
98 and become an important diagnostic indicator for DON poisoning monitoring [16,17].
99 Metabolic characteristics of DON in animals and description of metabolites related to
100 pathological conditions may be of great significance for understanding mechanisms and
101 pathways of DON, discovering biomarkers and establishing early diagnosis and
102 intervention [10,18]. Metabonomics is based on the modern molecular biology
103 technology and the method of combining the computer information technology, all
104 metabolic components in the cell, tissue or organ, especially for small molecular
105 substances monitoring, analyzes the source of the metabolites path, and make the
106 metabolism network topology, is currently the disease diagnosis, drug development and
107 toxicology analysis such as one of the most promising technology [19,20]. However, there
108 are few studies on the mechanism of action of mycotoxins such as DON based on
109 metabonomics.

110 Rabbit is an important model animal for the study of human diseases and nutrition,
111 and it is also a kind of high quality source of meat. With the continuous expansion of
112 rabbit breeding scale and the wide application of full price feed in rabbit industry, the
113 issue concerning contamination of mycotoxins in feed and potential threats to food safety
114 have attracted more and more attention from scientists [21]. As a kind of monogastric
115 herbivores and hindgut fermenter animal [22,23], the effect of the special intestinal
116 structure of rabbits on DON metabolism is not clear. At present, studies on the toxic
117 effects of DON mainly focus on humans, pigs and poultry, but studies on the metabolic
118 pathways and characteristics of DON in rabbits are very limited. Therefore, in this study,
119 the blood and urine samples of DON poisoning weaned rabbits will be analyzed using
120 the research strategy of LC-MS metabolomics, and the endogenous metabolites between
121 groups will be screened based on the biological information technology and the
122 metabolic pathways will be analyzed, so as to help search for potential biomarkers and
123 understand the mechanism of DON action in rabbits.

124 **Methods**

125 **Animal Experiment and Sample Collection**

126 Ingredient composition of the feedstuff of weaned rabbits supplied by Fat Rabbits Feed
127 Company (Taian, Shandong), as well as the concentration of DON, Zearalenone (ZEA)
128 and Aflatoxin B1 (AFB1), is listed in [Table 1](#). DON standards were diluted to 1.5 mg/mL
129 using sterile ultrapure water for later use. A total of 32 weaned rex rabbits (35-day-old,
130 male and female half) were divided evenly into two groups based on their weight,
131 namely the control group and DON group. Both groups of experimental rabbits,

132 individually placed in metabolic cages, were fed with the basic diet. Weaned rabbits in
 133 the DON group were intraperitoneally injected with 1.5 mg/kg b.w. DON every two days
 134 before feeding in the morning, while the rabbits in the control group were injected with
 135 the same amount of normal saline every two days in the same way. The experiment
 136 lasted for 25 days, that is a total of 12 injections to rabbits by the end of the trail. On day
 137 8, day 16 and 24 of experiment, 16 rabbits (8 rabbits each group) were selected for blood
 138 collection by ear vein before injecting DON (0h), as well as 1h, 2h, 3h, 4h and 6h after
 139 injecting DON, respectively. All collected blood coagulated naturally and centrifuged at
 140 1500g for 10 min in order to acquire serum samples, which stored at -70 °C for further
 141 analysis. On day 8, day 16 and 24 of experiment, the urine samples of 24 rabbits at empty
 142 stomach were collected, which centrifuged at 2,500 g for 10min and stored at -70 °C until
 143 sample procession, while the feces samples were collected and stored at -70 °C after
 144 drying at the same day. On day 25 of experiment, the serum and urine samples without
 145 injecting DON were collected for LC/MS analysis.

146

Table 1 The ingredient composition of the basic diets

Ingredient (%)		Calculated composition	
Maize	14	Dry matter	88.64
Soybean meal	17	Crude protein	20.05
Wheat bran	13	Crude fibre	18.78
Corn germ meal	19	Crude ash	10.45
Rice hulls	10	Crude fat	3.34
Soybean straw powder	7	Calcium	0.72
alfalfa	10	Total Phosphorus	0.55
Malt Sprout	5	Digestible energy (MJ/kg)	10.06
Sweet wormwood	3.5		
Premix material ¹	1.5		
Total	100		
Content of Mycotoxin (µg/kg) ²			
Deoxynivalenol (DON)	23.18		
Zearalenone (ZEA)	135.26		
Aflatoxin B1 (AFB1)	7.08		

147 ¹Premix material provided per kg feed: VA 12000 IU; VB 63.52mg; Choline 600mg; Biotin 0.2mg; VD 3100
 148 IU; VE 50mg; VK 31.5 mg; Fe 60mg; Zn 60mg; Cu 40mg; Mn 9mg; Se 0.2mg; Mountain flour 15000mg;
 149 NaCl 5000mg; Lysine 1500mg; Methionine 1000mg. ²Measured by LC-MS/MS method.

150 **Liquid chromatography-tandem mass spectrometry (LC-MS/MS)**

151 Standards of DON ($C_{15}H_{20}O_6$) and DOM-1 ($C_{15}H_{20}O_5$) purchased from Triplebond
152 Company (Guelph, Guelph, Canada). Sample preparation steps referred to the method
153 described by Brezina *et al.* (2014) [24]. Contents of DON and DOM-1 were detected via
154 LC-MS/MS following the protocol reported by Li *et al.* (2017) [14]. These detection
155 procedures were performed in the Institute of Quality Standards and Detection
156 Technology, Chinese Academy of Agricultural Sciences.

157 **Preparation of serum and urine samples**

158 All chemicals reagents used in the present study were analytically pure or
159 chromatographic grade. Methanol, chloroform, formic acid, water, acetonitrile were
160 purchased from CNW Company in German. l-2-chlorophenylalanine was purchased
161 from Hengchuang Biotechnology Company (Shanghai, China). In this study, 16 serum
162 and 16 urine samples from the two test groups were used for metabolomics analysis.
163 Firstly, 10 μ L of 2-chloro-l-phenylalanine (0.3 mg/mL) was dissolved in methanol as
164 internal standard, then mixed accurately 100 μ L serum samples and vortexed for 10 s.
165 Secondly, after 300 μ L of pre-cooling mixed solution with methanol and acetonitrile (2:1,
166 v/v) was added and vortexed for 1 min, these mixtures were extracted using ultrasound
167 in ice water bath for 10 min. Thirdly, these mixed solution was centrifuged at 13,000 rpm
168 for 15 min after stood at -20 °C for 30 min, then 200 μ L extracted supernatant were
169 filtered with 0.22 μ m pinhole filters and transferred to LC vial, which were stored at
170 -80 °C for future step. Lastly, all samples were mixed to be pooled sample at a certain ratio,
171 which acted as quality control samples (QC) sample and used to verify the results in

172 present research. For urine samples, the treatment procedure was in keeping with the
173 serum proceeding, except that 150 μ L urine specimen was centrifuged at 13,000 rpm for
174 10 min firstly, and then 100 μ L supernatant was accurately extracted and added into the
175 mix solution with internal standard.

176 **LC-MS analysis**

177 Metabolic profiling was monitored through an ACQUITY UPLC system (Waters
178 Corporation, Milford, USA) coupled with a Triple TOF 5600 System (AB SCIEX,
179 Framingham, MA). Meanwhile, ACQUITY UPLC BEH C8 (100 mm \times 2.1mm, 1.7 μ m) was
180 applied in ESI positive ion mode, while ACQUITY UPLC HSS T3 (100 mm \times 2.1 mm,
181 1.8 μ m) was used in negative ion mode. For positive ion mode, Mobile phase A was water
182 including 0.1% formic acid and B was acetonitrile with 0.1% formic acid, while for
183 negative ion mode, mobile phase A was water including 6.5 mM ammonium bicarbonate
184 and B was water and 95% methanol containing 6.5 mM ammonium bicarbonate. The
185 temperature of the column was 50 $^{\circ}$ C, the injection volume was 5 μ L and flow rate was at
186 0.35 mL/min. The elution gradient of HPLC and parameters of mass spectrum in this
187 experiment were listed in [Table S1](#) and [Table S2](#), respectively. Throughout the whole
188 analysis process, the QC samples were inserted at every 8 samples so as to evaluate the
189 repeatability.

190 **Data processing**

191 The raw data were transformed to mzML format via MSconverter, then peak extraction
192 was carried out by XCMS software. All data from positive and negative ion modes were

193 combined into a data matrix, which contains all the information extracted from the raw
194 data that can be used for subsequent analysis. The data matrix was exported into the
195 SIMCA software (Version 14.0, Umetrics, Sweden), then unsupervised principal
196 component analysis (PCA) was performed to observe the samples between the
197 population distribution and stability of the whole process of analysis, while supervised
198 orthogonal partial least-squares discriminant analysis (OPLS-DA) was used to
199 distinguish the overall difference in metabolic profile and screen the difference
200 metabolites between groups. For OPLS-DA analysis, variable important in projection
201 (VIP) greater than 1 were regarded as significant variables. The differential metabolites
202 between groups were screened on the basis of the combination of multidimensional
203 analysis and one-dimensional analysis. The screening criterion was the VIP values larger
204 than 1, coupling with *p* value from student's *t* test less than 0.05. In addition, the fold
205 change (FC) values referred to the ratio of the average content of metabolites in two
206 groups. Differential metabolites were identified by the rapid identification and analysis
207 software system (OSI/SMMS, Dalian, China). Analysis of identified metabolites and
208 pathway enrichment was based on public databases, including HMDB
209 (<http://www.hmdb.ca>), KEGG (<http://www.genome.jp/kegg/>) and LipidMaps
210 (<http://www.lipidmaps.org/>) databases.

211 **Statistical analysis**

212 The test data were analyzed by one-way ANOVA and *t* test, which expressed using mean
213 \pm standard deviation (SD). *p* < 0.05 was considered statistically significant, and *p* < 0.01
214 was considered extremely significant.

215 **Results and discussion**

216 **DON concentration in rabbit serum samples of different experimental periods.**

217 Studies have shown that the absorptivity of DON varied greatly among animals, for
218 example, the absorptivity of pigs, chickens, sheep and cattle was 82%, 19%, 9.9% and 1%,
219 respectively [10,25]. According to statistics, DON can reach the peak in blood after 15-30
220 min oral intake in pig, and reach the absorption peak within 3-4 h [26]. The results of this
221 study showed that the changes of DON concentration in serum of rabbits on day 8, 16
222 and 24 exhibited a highly consistent trend after DON was injected (Fig.1). Namely, the
223 content of DON in serum before injection was consistent with that of the control group,
224 while the content of DON in serum increased rapidly after injection, reached the peak at
225 1h after injection, and then decreased rapidly. At 4 hours after injection, the concentration
226 of DON was close to the control group, and 6 hours after injection, the concentration was
227 almost the same as that of the control group. Moreover, with the increase of injection
228 days, the concentration of DON did not change significantly in the same period,
229 indicating that DON can be rapidly metabolized in the blood, with almost no cumulative
230 effect. This result suggested that, in the clinical monitoring of DON poisoning, the
231 collection of blood samples has a strong timeliness, that is, blood indicators within 1-2 h
232 after ingestion are more meaningful for detection.

233 **Concentration of DON in urine and feces samples**

234 In this study, the content of DON in urine samples (Fig.2A) was 1,205.9 ng/ml, 1,590.65
235 ng/ml and 1,797.78 ng/ml respectively on the 8th, 16th and 24th day after DON
236 administration, while that in feces (Fig.2B) was 438 ng/ml, 1,213.4 ng/ml and

237 3,457.38ng/ml, respectively. In addition, with the increase of the number of DON
238 injections, the concentration of DON in urine and feces showed a significant trend of
239 increase, especially in feces. Interestingly, on the 8th day of the experiment, the
240 concentration of DON in feces was significantly lower than that in urine samples during
241 the same period, but the trend of increase was obvious. On the 24th day, the
242 concentration of DON in feces was significantly higher than that in urine, indicating that
243 with the prolongation of DON exposure period, the intestine becomes the main organ for
244 DON storage and excretion.

245 **Concentration of DOM-1 in urine and feces samples**

246 Microorganisms in the digestive tracts of animals and humans can degrade the toxic
247 DON to the non-toxic DOM-1, which usually as the most typical biomarker of DON
248 [27,28]. On the 8th, 16th and 24th day of the experiment, the content of DOM-1 in the
249 urine of DON group was 108.03 ng/ml, 129.75 ng/ml, 135.4 ng/ml (Fig.2C), and the
250 content of DOM-1 in feces was 57.13 ng/ml, 78.8 ng/ml, 130.3 ng/ml (Fig.2D), respectively,
251 which were significantly higher than those in the control group in the same period.
252 Moreover, with the increase of the number of DON injections, the concentration of
253 DOM-1 in urine and feces showed a significant trend of increase, and the content of
254 DOM-1 in urine was higher than that in feces in the same period. The amount of DOM-1
255 excreted in urine and feces were only about 5%-10% of the amount of DON excreted in
256 the same period, indicating that a large amount of DON were still excreted in the form of
257 DON after entering the body, and only a small amount will be decomposed into the
258 secondary metabolite DOM-1. The distribution of bacterial flora in the small intestine of

259 pigs are relatively less, as well as the degradation rate from DON to DOM-1 is also
260 relatively lower compared with poultry or ruminants, thus pigs are more sensitive to
261 DON [29]. Previous experiments proved that the destruction induced by DON in the
262 anterior segment of the small intestine for rabbits more serious than to the posterior
263 segment, suggesting that part of DON in the posterior segment is converted to DOM-1 by
264 intestinal microflora, thus relieve the destruction to the ileum [14].

265 **Multivariate analysis of LC-MS data**

266 Compared with the traditional HPLC-MS method, the LC-MS adopted in this study has
267 higher peak volume, separation degree and sensitivity, so it is more suitable for the
268 analysis of metabolomics for serum and urine samples of weaned rabbits. Test data of
269 serum and urine were uploaded severally into SIMCA for multivariate analysis in
270 present research. PCA was applied to analyze the entire allocation between samples and
271 stability of the whole analytic processing [18]. PCA score plots of total serum and urine
272 between two groups illustrated that the clustering of endogenous metabolites in the
273 DON group significantly changed compared with the control group (Fig.3A and Fig.3B).
274 In addition, it can be seen from Table 2 that both R^2X of serum ($R^2X = 0.543$) and urine
275 ($R^2X = 0.662$) were greater than 0.5, indicating that the model was reliable. OPLS-DA of
276 serum and urine samples were established respectively to further validate separation of
277 the metabolic profiles between two groups. As showed in OPLS-DA score plots (Fig.3C
278 and Fig.3D), either serum or urine samples between two groups were completely
279 separated, further indicating the metabolic characteristics in serum and urine were
280 significantly affected by DON addition. Furthermore, data from OPLS-DA model (Table

281 2) showed that the model parameters (R^2X , R^2Y and Q^2) of both of serum and urine were
 282 greater than 0.5, indicating that the OPLS-DA model was well established. Meanwhile,
 283 the results from 200 response permutation testing (RPT), which were used to examine the
 284 quality of the model in order to prevent the model from overfitting, indicated that the
 285 OPLS-DA models were well established (Fig.3E and Fig.3F). In brief, the multivariate
 286 analysis of LC-MS data proved that the data quality was reliable and the models were
 287 well established, as well as there were a significant difference between two groups,
 288 indicating the metabolic characteristics in serum and urine were significantly affected by
 289 DON exposure.

Table 2 Model quality parameters of multivariate analysis in serum and urine samples between two groups

Type	N	$R^2X(\text{cum})$	$R^2Y(\text{cum})$	$Q^2(\text{cum})$
Serum				
PCA	16	0.543		0.183
OPLS-DA	16	0.577	0.965	0.768
Urine				
PCA	16	0.662		0.37
OPLS-DA	16	0.527	0.993	0.956

Notes: N means the number of samples analyzed. R^2X and R^2Y refers to the cumulative interpretation rate of the model in the X-axis and Y-axis when modeling with the multivariate statistical analysis, or can be understood as the square of the percentage of the original data information retained at the X-axis or Y-axis direction, respectively. Q^2 means the parameters of the response ranking test, applying for measure whether the model is over-fitting.

290 Screening of differential metabolites

291 The differential metabolites between groups were screened on the basis of the
 292 combination of multi-dimensional analysis and single-dimensional analysis. According
 293 to $VIP \geq 1$ coupled with $p < 0.05$ as the screening criteria in this study, total of 179 serum
 294 features and 526 urine features (Table S3) were screened as discriminated variables. In

295 view of $FC > 1$ means up-regulation and $FC < 1$ means down-regulation of metabolites, 51
296 metabolites were upregulated and 128 were up-regulated in serum, while 327
297 metabolites were upregulated and 199 were down-regulated in urine samples. As a result,
298 26 metabolites in serum, as well as 36 metabolites in urine respectively were screened as
299 potential biomarkers based on the principle of p values from small to large (Table 3 and
300 Table 4). Furthermore, all the differential metabolites in serum and urine of rabbits were
301 analyzed applying VENN method, and the results showed that there are 15 differential
302 metabolites shared by serum and urine (Fig.4). As displayed in Table 5, these 15 shared
303 metabolites showed different regulatory trends in serum and urine. Although both urine
304 and blood are considered as the important physiological samples, the metabolic
305 pathways of DON in serum and urine were quite different in our research, and the
306 difference in urine was greater than that in blood obviously. Additionally, detection of
307 DON in urine was less dependent on the time of feeding, so we suggest that the relevant
308 detective indicators in urine may be more meaningful for clinical monitoring of DON.

309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324

325
326
327

Table 3 Significant metabolites in serum samples of rabbits

NO.	<i>m/z</i>	Metabolites	VIP	FC	Trend
1	225.18	Xylometazoline	1.038	2.159	↑ **
2	251.20	oxohexadecanoic acid	1.139	2.079	↑ **
3	253.22	Cadinene	4.309	2.077	↑ **
4	267.23	Avocadene	1.612	1.603	↑ **
5	476.11	Ochratoxin c	1.434	1.539	↑ **
6	511.47	10-hydroxy-16-hentriacontanone	2.105	1.527	↑ **
7	541.26	Cortolone-3-glucuronide	1.168	3.291	↑ **
8	639.54	Pregnanediol	3.106	2.260	↑ **
9	763.50	Narasin	1.262	1.661	↑ **
10	787.60	Tetradecanoylcarnitine	1.339	1.734	↑ **
11	851.52	Prostaglandin pge2 1-glyceryl ester	1.795	2.059	↑ **
12	862.61	3-o-sulfogalactosylceramide	7.265	2.947	↑ **
13	863.57	Latanoprost	7.242	3.996	↑ **
14	153.02	2,4-dihydroxybenzoic acid	1.926	0.307	↓ **
15	178.05	Hippuric acid	2.254	0.420	↓ **
16	359.19	Tricyclodehydroisohumulone	2.196	0.475	↓ **
17	417.12	Phlorizin	1.630	0.313	↓ **
18	457.33	N-decanoylglycine	2.642	0.414	↓ **
19	464.30	Glycocholic acid	2.215	0.300	↓ **
20	465.30	Cholesterol sulfate	3.711	0.658	↓ **
21	466.31	Gamma-linolenyl carnitine	2.558	0.626	↓ **
22	499.30	Corosin	1.670	0.599	↓ **
23	528.26	glycine	2.455	0.201	↓ **
24	772.62	Arachidonoyl serinol	5.511	0.581	↓ **
25	776.58	Leukotriene b4 ethanolamide	2.946	0.612	↓ **
26	833.54	11-hydroxyeicosatetraenoate glyceryl ester	10.444	0.204	↓ **

Notes: VIP means variable importance in projection. FC refers to the fold change, and FC>1 or FC<1, indicated by up arrows or down arrows respectively, were used to represent latively increased or decreased levels of the metabolites. ** means p < 0.01 between groups.

328

Table 4 Significant metabolites in urine samples of rabbits

NO.	m/z	Metabolites	VIP	FC	Trend
1	146.060	4-Hydroxyquinoline	3.615	4.440	↑ **
2	153.019	dihydroxybenzoic acid	4.667	2.972	↑ **
3	181.992	Saccharin	5.979	5.954	↑ **
4	201.023	Methylfuran	5.976	2.467	↑ **
5	279.134	Asp Ala Gly	7.454	3.436	↑ **
6	281.120	Asp-phe	3.989	2.372	↑ **
7	325.128	Dihydroconiferin	10.869	5.370	↑ **
8	327.142	S-methylmethionine	5.209	4.400	↑ **
9	339.093	3'-ketolactose	3.560	4.238	↑ **
10	344.172	His Gly Asn	4.867	5.016	↑ **
11	385.186	Pisumionoside	3.835	3.193	↑ **
12	401.164	Clusin	4.624	2.818	↑ **
13	411.199	Adapalene	4.274	2.887	↑ **
14	413.214	Miglitol	5.521	3.377	↑ **
15	413.215	Buclizine	4.259	2.579	↑ **
16	413.215	His Glu Lys	3.478	2.696	↑ **
17	445.077	2'-Hydroxyisoorientin	6.132	4.572	↑ **
18	447.094	Baicalin	7.575	4.450	↑ **
19	187.007	P-cresol sulfate	4.568	0.427	↓ **
20	194.081	N-Phenylacetyl glycine	5.480	0.520	↓ **
21	212.005	Indoxyl sulfate	9.501	0.509	↓ **
22	255.232	Ethyl tetradecanoate	8.553	0.519	↓ **
23	281.119	Phenprocoumon	3.557	0.573	↓ **
24	285.113	Matricarin	9.843	0.418	↓ **
25	295.097	Gamma-l-glutamyl-l-methionine sulfoxide	6.878	0.374	↓ **
26	301.143	6-ketoestriol	3.694	0.210	↓ **
27	313.107	Sappanone A Dimethyl ether	7.724	0.353	↓ **
28	313.274	Ricinoleic Acid methyl ester	4.475	0.570	↓ **
29	315.123	Sorgolactone	8.085	0.567	↓ **
30	329.102	2'-Hydroxy-4',6'-dimethoxychalcone	12.136	0.426	↓ **
31	331.284	Glycerol 1-hexadecanoate	3.942	0.575	↓ **
32	338.342	Erucamide	6.969	0.562	↓ **
33	341.305	Hexadecyl Acetyl Glycerol	3.293	0.577	↓ **
34	348.144	Val Asp Asp	8.709	0.453	↓ **
35	349.148	Trp Ser Gly	5.076	0.422	↓ **
36	353.100	Americanola	5.193	0.345	↓ **

Notes: VIP means variable importance in projection. FC refers to the fold change, and FC>1 or FC<1, indicated by up arrows or down arrows respectively, were used to represent latively increased or decreased levels of the metabolites. ** means p < 0.01 between groups.

Table 5 Shared differential metabolites in serum and urine samples of rabbits

Shared metabolites	VIP		FC		Trend	
	Serum	Urine	Serum	Urine	Serum	Urine
DL-Indole-3-lactic acid	1.10	1.62	1.89	0.73	↑**	↓**
N-[(3a,5b,7a)-3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-glycine	4.88	2.45	0.35	0.20	↓**	↓**
2'-Hydroxy-4',6'-dimethoxychalcone	12.14	2.02	0.43	0.47	↓**	↓**
2,4-dihydroxybenzoic acid	4.67	1.93	2.97	0.31	↑**	↓**
Kiwiionoside	1.90	1.01	4.26	0.28	↑**	↓**
11-hydroxyeicosatetraenoate glyceryl ester	1.24	10.44	0.65	0.20	↓**	↓**
Dictyoquinazol b	1.11	1.57	1.73	0.21	↑**	↓**
N-decanoylglycine	2.01	2.64	3.18	0.41	↑**	↓**
Mycotoxin t 2	7.19	1.19	5.26	0.32	↑**	↓**
Ascorbyl palmitate	1.13	1.53	0.66	1.66	↓**	↑**
Met His Lys	2.81	1.45	0.62	0.74	↓**	↓**
(2-methyl-3-furyl)thio-2-butanone	9.76	2.20	2.40	0.44	↑**	↓**
Indoxyl sulfate	9.50	1.63	0.51	2.02	↓**	↑**
Glycochenodeoxycholic acid 3-glucuronide	1.16	1.02	0.60	0.53	↓**	↓**
MG(18:0/0:0/0:0)	2.65	1.85	0.61	1.35	↓**	↑**

Notes: VIP means variable importance in projection. FC refers to the fold change, and $FC > 1$ or $FC < 1$, indicated by up arrows or down arrows respectively, were used to represent latively increased or decreased levels of the metabolites. ** means $p < 0.01$ between groups.

335 Metabolite profiling

336 To better understand the effect of identified metabolites in serum and urine samples of
 337 rabbits of different groups, the enrichment of metabolic pathway was analyzed
 338 separately. Firstly, all the metabolites in each group, with $FC < 0.67$ or $FC > 1.5$, were
 339 selected and putted into MetaboAnalyst, which as a platform of comprehensive analysis
 340 for quantitative metabonomics data based on web. Secondly, the metabolites were
 341 matched according to the KEGG metabolic pathway database. Finally, the visualized
 342 results of metabolic pathway analysis are illustrated in [Figure 5](#). As shown in [Fig.5](#), the

343 main metabolic pathways in serum samples disturbed by DON included:
344 Glycerophospholipid metabolism, Tryptophan metabolism, Pentose and glucuronate
345 interconversions, and Ether lipid metabolism, while their pathway impact were 22%, 14%,
346 14% and 14% in order. At the same time, the main metabolic pathways in urine samples
347 included: Caffeine metabolism, Glycine, serine and threonine metabolism, Terpenoid
348 backbone biosynthesis, Pentose and glucuronate interconversions, while their pathway
349 impact were 30%, 27%, 18% and 14% in order. Additionally, both the number of
350 metabolic pathways and that of differential metabolites induced by DON in urine
351 samples were higher than those in blood samples. In conclusion, the pathogenic
352 mechanism of DON includes multiple levels, involving the metabolism of substances
353 such as sugar, fat and protein, as well as their metabolic pathways, indicating that DON
354 poisoning is caused by multiple factors acting on multiple links.

355 **Identified metabolites and disease induced by DON**

356 Metabolites in blood and urine are often the key to the diagnosis of diseases. In particular,
357 metabolites in urine, which are the terminal metabolites in living organisms, are the most
358 complex and most likely to reflect diseases in the body [30]. In order to further analysis
359 the correlation between identified metabolites in serum and urine of rabbits induced by
360 DON and specific diseases, the Pub Chem ID of the identified metabolites were uploaded
361 into MetaboAnalyst platform and enrichment analysis were performed using package
362 globaltest based on Quantitative enrichment analysis (QEA), which aimed to describe the
363 correlation between compound concentration profiles and clinical outcomes. As a result,
364 total of 22 kinds of diseases in serum samples and that of 65 kinds of diseases in urine

365 were screened, which associated with the identified metabolites of rabbits interfered by
366 DON (Table S4). In order to reveal the correlation between disease and identified
367 metabolites induced by DON for rabbits, the histograms have been drawn based on the
368 top 14 associated diseases as the ordinate, and the number of associated metabolites as
369 the abscissa (Fig.6). For serum samples, the associated diseases of the top three were
370 Schizophrenia, Different seizure disorders, and Cirrhosis, with the number of the
371 associated metabolites at 26, 24 and 23 in order. While in urine samples, associated
372 diseases of the top three were Schizophrenia, Lung Cancer and Medium Chain Acyl-Coa
373 Dehydrogenase Deficiency, with the number of the associated metabolites at 32, 32 and
374 28 in order. The correlating network diagram has been established via Cytoscape
375 software, which aimed to further understand the correlation between specific diseases
376 associated with identified metabolites affected by DON. It can be seen from Fig.7, for
377 serum samples, Refractory localization-related epilepsy was correlated to the multiple
378 diseases, while for urine samples, Short-chain 3-hydroxyacyl-coa Dehydrogenase
379 deficiency, X-linked creatine-transporter defect Carbamoyl Phosphate Synthetase
380 Deficiency and Sarcosinemia were correlated to the multiple diseases. The results of this
381 study indicated that DON addition would cause changes of some metabolites related to
382 specific diseases in the serum and urine of weaned rabbits. It is of great concern that the
383 first related disease in both of serum and urine samples were schizophrenia, and
384 multiple identified metabolites were associated with neurological diseases.

385 In recent years, numerous researches found that there exists a complex neuroendocrine
386 network which connect the brain and gastrointestinal tract, so it is called "brain-gut axis"

387 [31].¹ As a two-way pathway between the central nervous system and the gastrointestinal
388 tract, abnormal signal transduction is associated with numerous diseases, such as
389 inflammatory, functional gastrointestinal diseases and feeding disorders, and so on [32].
390 DON can act on the central nervous system through quickly the blood-brain barrier,
391 cause changes in certain chemicals, and then lead to eating less or refusing food [33,34].
392 Consequently, it is need to further investigate whether chronically low intake of DON is a
393 risk factor for psychiatric disorders. A growing number of studies have demonstrated
394 that DON can induce changes in intestinal microbialflora, whose metabolites are
395 important mediators linking the intestinal tract and the brain-gut-axis [35]. It also have
396 been shown that the disorder of intestinal flora are related to neurological diseases such
397 as depression [36]. Therefore, the next step on the researchs of the relationship among
398 DON, metabolites, intestinal flora and neuromodulation in vivo will help us to further
399 understand the pathogenic mechanism of DON, which beneficial to prevent and control
400 DON contamination.

401

402

403 **Additional files**

404 Additional file 1. **Table S1**. The elution gradient of HPLC in this experiment; **Table S2**.
405 The parameters of mass spectrum in this experiment. (DOC, 41kb)

406 Additional file 2. **Table S3**. Differential metabolites in serum and urine. (XLS, 493kb)

407 Additional file 3. **Table S4**. Associated diseases and metabolites in serum and urine. (XLS,
408 13kb)

409

410 **Abbreviations**

411 DON: deoxynivalenol; DOM: de-epoxidation deoxynivalenol; PCA: principal component
412 analysis; OPLS-DA: orthogonal partial least-squares discriminant analysis; VIP: variable
413 important in projection; FC: fold change; RPT: 200 response permutation testing; LC-MS:
414 Liquid chromatography-tandem mass spectrometry;

415 **Acknowledgement**

416 We would like to thank our anonymous reviewers and our colleagues from the Animal
417 Nutrition Laboratory for their valuable critiques and suggestions.

418 **Funding**

419 This work was supported by the Modern Agro-industry Technology Research system
420 (CARS-43-B-1), Natural Science Foundation of Shandong Province (ZR2018QC004,
421 ZR2018MC025), Key Research and Development Project of Shandong Province
422 (2019GNC106007) and Funds from the Shandong 'Double Tops' Program and Youth
423 Science.

424 **Availability of data and materials**

425 The datasets used and/or analysed during the current study are available from the
426 corresponding author on reasonable request.

427 **Authors' contributions**

428 Li F.C. designed the study. Huang L.B. performed the experiments and wrote a draft of
429 the paper. Liu Q.C. performed animal trial. Wang P.W. analyzed the data. Chen H.J.
430 contributed reagents/materials/analysis tools. Wang C.Y. conceived and designed the
431 experiments and revised the paper.

432 **Ethics approval and consent to participate**

433 The experimental protocol concerning live animals in this study has been ratified by the
434 Animal Protection Committee of Shandong Agricultural University (Certification No.
435 ACSA-2019-0025), and the operation procedures are in compliance with the ethical
436 regulations of laboratory animals promulgated by the Ministry of Science and
437 Technology of China.

438 **Consent for publication**

439 Not applicable.

440 **Competing interests**

441 The authors declare no conflict of interest.

442

443 **Author details**

444 ¹Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control
445 and Prevention, Shandong Agricultural University, 61 Daizong Street, Taian City,
446 Shandong Province, 271018, China

447

448 **References**

- 449 1. Lee HJ, Ryu D. Worldwide Occurrence of Mycotoxins in Cereals and Cereal-Derived
450 Food Products: Public Health Perspectives of Their Co-occurrence. *J.Agric.Food*
451 *Chem.* 2017; 65(33): 7034-51. <https://doi.org/10.1021/acs.jafc.6b04847>
- 452 2. Bryla M, Waskiewicz A, Ksieniewicz-Wozniak E, Szymczyk K, Jedrzejczak R.
453 Modified Fusarium Mycotoxins in Cereals and Their Products-Metabolism,

- 454 Occurrence, and Toxicity: An Updated Review. *Molecules*. 2018; 23: 963.
455 <https://doi.org/10.3390/molecules23040963>
- 456 3. Liao Y, Peng Z, Chen L, Nussler AK, Liu L, Yang W. Deoxynivalenol, gut microbiota
457 and immunotoxicity: A potential approach? *Food Chem Toxicol*. 2018; 112: 342-54.
458 <https://doi.org/10.1016/j.fct.2018.01.013>
- 459 4. Cimbalo A, Alonso-Garrido M, Font G, Manyes L. Toxicity of mycotoxins *in vivo* on
460 vertebrate organisms: A review. *Food. Chem. Toxicol*. 2020; 137: 111161.
461 <https://doi.org/10.1016/j.fct.2020.111161>
- 462 5. Ghareeb K, Awad WA, Bohm J, Zebeli Q. Impacts of the feed contaminant
463 deoxynivalenol on the intestine of monogastric animals: poultry and swine. *J. Appl*
464 *Toxicol*. 2015; 35 (4): 327-37. <https://doi.org/10.1002/jat.3083>
- 465 6. Pestka JJ, Islam Z, Amuzie CJ. Immunochemical assessment of deoxynivalenol tissue
466 distribution following oral exposure in the mouse. *Toxicol. Lett*. 2008; 178 (2): 83-87.
467 <https://doi.org/10.1016/j.toxlet.2008.02.005>
- 468 7. Wan D, Huang L, Pan Y, Wu Q, Chen D, Tao Y, Wang X, Liu Z, Li J, Wang L, Yuan Z.
469 Metabolism, Distribution, and Excretion of Deoxynivalenol with Combined
470 Techniques of Radiotracing, High-Performance Liquid Chromatography Ion Trap
471 Time-of-Flight Mass Spectrometry, and Online Radiometric Detection. *J.Agric.Food*
472 *Chem*. 2014; 62(1): 288-96. <https://doi.org/10.1021/jf4047946>
- 473 8. Warth B, Sulyok M, Fruhmann P, Mikula H, Berthiller F, Schuhmacher R, Hametner
474 C, Abia WA, Adam G, Frohlich J, Krska R. Development and validation of a rapid
475 multi-biomarker liquid chromatography/tandem mass spectrometry method to

- 476 assess human exposure to mycotoxins. *Rapid. Commun.Mass.Spectrom.* 2012; 26(13):
477 1533-40. <https://doi.org/10.1002/rcm.6255>
- 478 9. Wu Q, Dohnal V, Huang L, Kuča K, Yuan Z. Metabolic pathways of trichothecenes.
479 *Drug Metab.Rev.* 2010; 42 (2): 250-67. <https://doi.org/10.1021/jf4047946>
- 480 10. Schwartz-Zimmermann HE, Fruhmann P, Danicke S, Wiesenberger G, Caha S,
481 Weber J, Berthiller F. Metabolism of deoxynivalenol and deepoxy-deoxynivalenol in
482 broiler chickens, pullets, roosters and turkeys. *Toxins.* 2015; 7 (11): 4706-29.
483 <https://doi.org/10.3390/toxins7114706>
- 484 11. Turner PC, Hopton RP, Lecluse Y, White KL, Fisher J, Lebailly P. Determinants of
485 urinary deoxynivalenol and de-epoxy deoxynivalenol in male farmers from
486 Normandy, France. *J. Agric. Food Chem.* 2010; 58 (8): 5206-12.
487 <https://doi.org/10.1021/jf100892v>
- 488 12. Danicke S, Valenta H, Ganter M, Brosig B, Kersten S, Diesing AK, Kahlert S,
489 Panther P, Kluess J, Rothkotter HJ. Lipopolysaccharides (LPS) modulate the
490 metabolism of deoxynivalenol (DON) in the pig. *Mycotoxin Res.* 2014; 30 (3): 161-70.
491 <https://doi.org/10.1007/s12550-014-0201-7>
- 492 13. Schwartz-Zimmermann HE, Hametner C, Nagl V, Fiby I, Macheiner L, Winkler J,
493 Danicke S, Clark E, Pestka JJ, Berthiller F. Glucuronidation of deoxynivalenol (DON)
494 by different animal species: identification of iso-DON glucuronides and
495 iso-deepoxy-DON glucuronides as novel DON metabolites in pigs, rats, mice, and
496 cows. *Arch. Toxicol.* 2017; 91(12): 3857-72. <https://doi.org/10.1007/s00204-017-2012-z>

- 497 14. Li F, Wang J, Huang L, Chen H, Wang C. Effects of Adding *Clostridium sp.* WJ06 on
498 Intestinal Morphology and Microbial Diversity of Growing Pigs Fed with Natural
499 Deoxynivalenol Contaminated Wheat. *Toxins*. 2017; 9: 83.
500 <https://doi.org/10.3390/toxins9120383>
- 501 15. Wu L, W WC, Huang R, Cui Z, He L, Y J, Duan J, Li T, Wang JQ. Deoxynivalenol
502 residues in edible tissue of infested pig. *J. Food. Agric. Environ.* 2013;11:1129-33.
- 503 16. Gratz SW, Currie V, Duncan G, Jackson D. Multimycotoxin Exposure Assessment in
504 UK Children Using Urinary Biomarkers-A Pilot Survey. *J. Agric. Food Chem.* 2020;
505 68 (1): 351-57. <https://doi.org/10.1021/acs.jafc.9b03964>
- 506 17. Hopton RP, Turner E, Burley VJ, Turner PC, Fisher J. Urine metabolite analysis as a
507 function of deoxynivalenol exposure: an NMR-based metabolomics investigation.
508 *Food Addit.Contam.* 2010; 27(2):255-61. <https://doi.org/10.1080/19440040903314015>
- 509 18. Xu Y, Ji J, Wu H, Pi F, Blazenovic I, Zhang Y, Sun X. Untargeted GC-TOFMS-based
510 cellular metabolism analysis to evaluate ozone degradation effect of deoxynivalenol.
511 *Toxicon.* 2019; 168:49-57. <https://doi.org/10.1016/j.toxicon.2019.06.022>
- 512 19. Saia S, Fragasso M, De Vita P, Beleggia R. Metabolomics Provides Valuable Insight
513 for the Study of Durum Wheat: A Review. *J. Agric. Food Chem.* 2019; 67(11): 3069-85.
514 <https://doi.org/10.1021/acs.jafc.8b07097>
- 515 20. He H, An F, Huang Q, Kong Y, He D, Chen L, Song H. Metabolic effect of AOS-iron
516 in rats with iron deficiency anemia using LC-MS/MS based metabolomics. *Food. Res.*
517 *Int.* 2020; 130. <https://doi.org/10.1016/j.foodres.2019.108913>

- 518 21. Greco MV, Pardo AG, Ludemann V, Martino PE, Pose GN. Mycoflora and natural
519 incidence of selected mycotoxins in rabbit and Chinchilla feeds. *Sci. World. J.* 2012;
520 2012: 956056. <https://doi.org/10.1100/2012/956056>
- 521 22. Zhu Y, Wang C, Li F. Impact of dietary fiber/starch ratio in shaping caecal microbiota
522 in rabbits. *Can J. Microbiol.* 2015;61(10): 771-84. <https://doi.org/10.1139/cjm-2015-0201>
- 523 23. Wang C, Zhu Y, Li F, Huang L. The Effect of *Lactobacillus* isolates on growth
524 performance, immune response, intestinal bacterial community composition of
525 growing Rex Rabbits. *J. Anim Physiol. Anim Nutr.* 2017; 101(5): e1-e9.
526 <https://doi.org/e1-e13.10.1111/jpn.12629>
- 527 24. Brezina U, Valenta H, Rempe I, Kersten S, Humpf HU, Danicke S. Development of a
528 liquid chromatography tandem mass spectrometry method for the simultaneous
529 determination of zearalenone, deoxynivalenol and their metabolites in pig serum.
530 *Mycotoxin. Res.* 2014; 30 (3):171-86. <https://doi.org/10.1007/s12550-014-0200-8>
- 531 25. Barnett AM, Roy NC, McNabb WC, Cookson AL. The interactions between
532 endogenous bacteria, dietary components and the mucus layer of the large bowel.
533 *Food Funct.* 2012; 3(7): 690–9. <https://doi.org/10.1039/c2fo30017f>
- 534 26. Rotter BA, Prelusky DB, Pestks JJ. Toxicology of deoxynivalenol (vomitoxin).
535 *J. Toxicol. Environ. Health.* 1996; 48:1–34. <https://doi.org/10.1080/713851046>
- 536 27. Frey JC, Pell AN, Berthiaume R, Lapierre H, Lee S, Ha JK, Mendell JE, Angert ER.
537 Comparative studies of microbial populations in the rumen, duodenum, ileum and
538 faeces of lactating dairy cows. *J. Appl. Microbiol.* 2010; 108 (6):1982-93.
539 <https://doi.org/10.1111/j.1365-2672.2009.04602.x>

- 540 28. Ji C, Fan Y, Zhao L. Review on biological degradation of mycotoxins. *Anim. Nutr.*
541 2016; 2(3): 127-33. <https://doi.org/10.1016/j.aninu.2016.07.003>
- 542 29. Lessard M, Savard C, Deschene K, Lauzon K, Pinilla VA, Gagnon CA, Lapointe J,
543 Guay F, Chorfi Y. Impact of deoxynivalenol (DON) contaminated feed on intestinal
544 integrity and immune response in swine. *Food. Chem. Toxicol.* 2015; 80: 7-16.
545 <https://doi.org/10.1016/j.fct.2015.02.013>
- 546 30. Fernandez-Ochoa A, Quirantes-Pine, R, Borrás-Linares I, Gemperline D,
547 Consortium PC, Alarcon Riquelme ME, Beretta L, Segura-Carretero A. Urinary and
548 plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic
549 sclerosis patients. *J. Pharm. Biomed. Anal.* 2019; 162: 82-90.
550 <https://doi.org/10.1016/j.jpba.2018.09.021>
- 551 31. Clemmensen C, Muller TD, Woods SC, Berthoud HR, Seeley RJ, Tschöp MH.
552 Gut-Brain Cross-Talk in Metabolic Control. *Cell.* 2017; 168 (5): 758-74.
553 <https://doi.org/10.1016/j.cell.2017.01.025>
- 554 32. Labanski A, Langhorst J, Engler H, Elsenbruch S. Stress and the brain-gut axis in
555 functional and chronic-inflammatory gastrointestinal diseases: A transdisciplinary
556 challenge. *Psychoneuroendocrinol.* 2020; 111: 104501.
557 <https://doi.org/10.1016/j.psyneuen.2019.104501>
- 558 33. Wang X, Chen X, Cao L, Zhu L, Zhang Y, Chu X, Zhu D, Rahman SU, Peng C, Feng S,
559 Li Y, Wu J. Mechanism of deoxynivalenol-induced neurotoxicity in weaned piglets is
560 linked to lipid peroxidation, dampened neurotransmitter levels, and interference

561 with calcium signaling. *Ecotoxicol. Environ. Saf.* 2020; 194:110382.
562 <https://doi.org/10.1016/j.ecoenv.2020.110382>

563 34. Miro-Abella E, Torrell H, Herrero P, Canela N, Arola L, Borrull F, Ras R, Fontanals N.
564 Monitoring and evaluation of the interaction between deoxynivalenol and gut
565 microbiota in Wistar rats by mass spectrometry-based metabolomics and
566 next-generation sequencing. *Food. Chem. Toxicol.* 2018; 121: 124-130.
567 <https://doi.org/10.1016/j.fct.2018.08.006>

568 35. Long-Smith C, O'Riordan KJ, Clarke G, Stanton C, Dinan TG, Cryan JF.
569 Microbiota-Gut-Brain Axis: New Therapeutic Opportunities. *Annu. Rev. Pharmacol.*
570 *Toxicol.* 2020; 60: 477-502. <https://doi.org/10.1146/annurev-pharmtox-010919-023628>

571 36. Peng Z, Chen L, Xiao J, Zhou X, Nussler AK, Liu L, Liu J, Yang W. Review of
572 mechanisms of deoxynivalenol-induced anorexia: The role of gut microbiota. *J.*
573 *Appl. Toxicol.* 2017; 37(9): 1021-29. <https://doi.org/10.1002/jat.3475>

574
575
576

Figures




Figure 1

The concent of DON in serum samples ($M \pm SD$, $n=8$). 8d,16d and 24d refers to the day of DON exposure. x-axis refers to different blood sampling times at same trial day. Control and DON refers to different group.




Figure 1

The concent of DON in serum samples ($M \pm SD$, $n=8$). 8d,16d and 24d refers to the day of DON exposure. x-axis refers to different blood sampling times at same trial day. Control and DON refers to different group.




Figure 1

The concent of DON in serum samples ($M \pm SD$, $n=8$). 8d,16d and 24d refers to the day of DON exposure. x-axis refers to different blood sampling times at same trial day. Control and DON refers to different group.




Figure 2

The concentration DON and DOM-1 in urine (A,C) and feces (B,D) samples at different period of DON exposure ($Mean \pm SD, n=8$). Control and DON refers to different group.




Figure 2

The concentration DON and DOM-1 in urine (A,C) and feces (B,D) samples at different period of DON exposure (Mean±SD,n=8). Control and DON refers to different group.




Figure 2

The concentration DON and DOM-1 in urine (A,C) and feces (B,D) samples at different period of DON exposure (Mean±SD,n=8). Control and DON refers to different group.




Figure 3

Multivariate analysis of serum (left) and urine (right) metabolites between two groups. A,B refers to PCA score plots, C,D refers to OPLS-DA score plots, and E,F represent the result of RPT.




Figure 3

Multivariate analysis of serum (left) and urine (right) metabolites between two groups. A,B refers to PCA score plots, C,D refers to OPLS-DA score plots, and E,F represent the result of RPT.




Figure 3

Multivariate analysis of serum (left) and urine (right) metabolites between two groups. A, B refers to PCA score plots, C, D refers to OPLS-DA score plots, and E, F represent the result of RPT.




Figure 4

Differential metabolites analysis of serum and urine by venn method




Figure 4

Differential metabolites analysis of serum and urine by venn method




Figure 4

Differential metabolites analysis of serum and urine by venn method




Figure 5

The pathway analysis of the identified metabolites in serum (left) and urine (right) of rabbits. Selected metabolites based on FC < 0.67 or >1.50. X-axis represents the pathway impact and y-axis represents the pathway enrichment. Larger sizes and darker colors represent higher pathway enrichment and higher pathway impact values.




Figure 5

The pathway analysis of the identified metabolites in serum (left) and urine (right) of rabbits. Selected metabolites based on FC < 0.67 or >1.50. X-axis represents the pathway impact and y-axis represents the pathway enrichment. Larger sizes and darker colors represent higher pathway enrichment and higher pathway impact values.




Figure 5

The pathway analysis of the identified metabolites in serum (left) and urine (right) of rabbits. Selected metabolites based on FC < 0.67 or >1.50. X-axis represents the pathway impact and y-axis represents the pathway enrichment. Larger sizes and darker colors represent higher pathway enrichment and higher pathway impact values.




Figure 6

The bar graph of the correlation of specific diseases and associated metabolites in serum (left) and urine (right). X-axis represents the number of associated metabolites and y-axis represents the specific diseases profiled by QEA.




Figure 6

The bar graph of the correlation of specific diseases and associated metabolites in serum (left) and urine (right). X-axis represents the number of associated metabolites and y-axis represents the specific diseases profiled by QEA.




Figure 6

The bar graph of the correlation of specific diseases and associated metabolites in serum (left) and urine (right). X-axis represents the number of associated metabolites and y-axis represents the specific diseases profiled by QEA.




Figure 7

The network of the correlation of associated diseases in serum (left) and urine (right).




Figure 7

The network of the correlation of associated diseases in serum (left) and urine (right).




Figure 7

The network of the correlation of associated diseases in serum (left) and urine (right).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [TableS1andTableS2.doc](#)
- [TableS1andTableS2.doc](#)
- [TableS1andTableS2.doc](#)
- [TableS3Differentialmetabolitesinserumandurine.xls](#)
- [TableS3Differentialmetabolitesinserumandurine.xls](#)
- [TableS3Differentialmetabolitesinserumandurine.xls](#)
- [TableS4Diseasesandmetabolitesinserumandurine.csv](#)
- [TableS4Diseasesandmetabolitesinserumandurine.csv](#)
- [TableS4Diseasesandmetabolitesinserumandurine.csv](#)